CA-RECOVER
14.10.2021 16:07:08 CEST | Business Wire | Press release
Global fashion retailer REVOLVE has partnered with Recover™, leading producer in recycled cotton fiber, to introduce a sustainable denim collection with REVOLVE-owned brand Lovers and Friends.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211014005745/en/
Recover™ is an innovative textile fiber producer that has been pioneering sustainable materials and recycling since 1947. The company recycles post-industrial and post-consumer cotton waste, replacing the need to cultivate cotton, dramatically reducing water waste, limiting the use of dyes through its RColorBlend system, and reducing textile landfill waste.
Launched today, the range features 14 styles of jeans, each produced with a minimum of 15% Recover™ recycled cotton fiber made from post-consumer denim.
The pairing of the valuable resources Recover™ provides with Lovers and Friends underscores REVOLVE’s commitment to sustainable fashion, and leading the change towards a more circular, and enduring fashion system.
“REVOLVE has a responsibility to contribute positively to the longevity of our industry and ecosystem, and for us, this process begins at home. We have worked with thousands of brands and suppliers, and Recover™ is unparalleled in its expertise and long-term focus. We are proud to partner with this multigeneration, family-owned business to deliver the strongest messaging and product to our consumers with one of our most recognizable owned brands, Lovers and Friends.” - Michael Mente, Co-CEO and Co-Founder REVOLVE Group.
“It is great to launch this sustainable collection today with such an iconic American brand and denim product. By incorporating Recover´s lowest-impact, highest-quality recycled fiber into the Lovers and Friends denim line we have created a strong collaboration that is helping to bring sustainable fashion closer to the consumer. Recover™ aims to scale its recycled cotton fiber production to help more brands meet their sustainable goals and achieve circular fashion for all.” - Alfredo Ferre, CEO Recover™
Recover™ has already supplied its recycled cotton and cotton blend fibers to illustrious brands such as Wrangler, H&M Group, Tommy Hilfiger, G-Star, The North Face, Billabong and Primark among many others during its rich history.
“Recover™ is building a strong ingredient brand, with the mission to dramatically enhance the environmental value of the garment for the final customer. We’ve taken special care in the way we inform them about the impact of this collection in collaboration with REVOLVE. The hang tag includes a QR code that leads to more information about the environmental savings, such as water, and compares them to day-to-day activities, like the number of showers, to make them more understandable.” – Boris Mercier, Marketing Director Recover™
By adding REVOLVE and Lovers and Friends to its portfolio, Recover™ moves one step closer to achieving its mission of “circular fashion for all”.
Price Range: $128-$158. Available at REVOLVE.com
About Recover™
Recover™ is a leading material sciences company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends. Its premium, environmentally friendly, and cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to achieve circular fashion for all.
As a fourth-generation, family-owned company with over a 70-year history in the textile industry, Recover™ is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change-makers to meet the industry’s sustainability targets. Recover™ was honored in Fast Company ’s Innovation by Design Awards for 2021 in the Sustainability and Materials categories.
For more information, visit www.recoverfiber.com and follow @recoverfiber on social media.
About REVOLVE
REVOLVE is the next-generation fashion retailer for Millennial and Generation Z consumers. As a trusted, premium lifestyle brand and a go-to source for discovery and inspiration, REVOLVE delivers an engaging customer experience from a vast yet curated offering of over 45,000 products. Founded in Los Angeles in 2003 by co-CEOs, Michael Mente and Mike Karanikolas, REVOLVE’s family of brands includes their luxury offering, FWRD.com, and a portfolio of owned brands such as Lovers and Friends, Tularosa, NBD and RAYE. For more information, please visit www.revolve.com , or find us on Instagram , Twitter, Pinterest, and Facebook.
About Lovers and Friends
Inspired by the laid back Los Angeles lifestyle in which the brand was founded, Lovers and Friends exudes effortless style and wearability, creating a signature sexy-meets-chic look with a California-cool sensibility. Lovers and Friends is designed for the girl who is a go-getter and fun-seeker. Every trend-inspired outfit is perfectly curated for her event-filled social schedule, whether she's meeting her girls for brunch or jet-setting to another coast. Sometimes sassy, sometimes sweet but always chic - she is both a LOVER and a FRIEND.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005745/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom